CoChat

Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma

Jenner, Matthew W., Leone, Paola E., Walker, Brian A., Ross, Fiona M., Johnson, David C., Gonzalez, David, Chiecchio, Laura, Dachs Cabanas, Elisabet, Paolo Dagrada, Gian, Nightingale, Mathew, Protheroe, Rebecca K. M., Stockley, David, Else, Monica, Dickens, Nicholas J., Cross, Nicholas C. P., Davies, Faith E., Morgan, Gareth J. · 2007 · Blood
Cited by 141

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

We performed fluorescent in situ hybridization (FISH) for 16q23 abnormalities in 861 patients with newly diagnosed multiple myeloma and identified deletion of 16q [del(16q)] in 19.5%. In 467 cases in which demographic and survival data were available, del(16q) was associated with a worse overall survival (OS). It was an independent prognostic marker and conferred additional adverse survival impact in cases with the known poor-risk cytogenetic factors t(4;14) and del(17p). Gene expression profiling and gene mapping using 500K single-nucleotide polymorphism (SNP) mapping arrays revealed loss of heterozygosity (LOH) involving 3 regions: the whole of 16q, a region centered on 16q12 (the location of CYLD), and a region centered on 16q23 (the location of the WW domain-containing oxidoreductase gene WWOX). CYLD is a negative regulator of the NF-κB pathway, and cases with low expression of CYLD were used to define a “low-CYLD signature.” Cases with 16q LOH or t(14;16) had significantly reduced WWOX expression. WWOX, the site of the translocation breakpoint in t(14;16) cases, is a known tumor suppressor gene involved in apoptosis, and we were able to generate a “low-WWOX signature” defined by WWOX expression. These 2 genes and their corresponding pathways provide an important insight into the potential mechanisms by which 16q LOH confers poor prognosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2007-02-075069

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 141

Metadata

Authors
Jenner, M. W., Leone, P. E., Walker, B. A., Ross, F. M., Johnson, D. C., Gonzalez, D., Chiecchio, L., Dachs Cabanas, E., Paolo Dagrada, G., Nightingale, M., Protheroe, R. K. M., Stockley, D., Else, M., Dickens, N. J., Cross, N. C. P., Davies, F. E., & Morgan, G. J.
Venue
Blood
Published
2007-11-01
Volume
110
Issue
9
Pages
3291-3300
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W1965481841
Cited by
141
References
4
FWCI
6.05
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. https://app.cochat.ai/papers/10.1182/blood-2007-02-075069
The paper
Jenner, M. W., Leone, P. E., Walker, B. A., Ross, F. M., Johnson, D. C., Gonzalez, D., Chiecchio, L., Dachs Cabanas, E., Paolo Dagrada, G., Nightingale, M., Protheroe, R. K. M., Stockley, D., Else, M., Dickens, N. J., Cross, N. C. P., Davies, F. E., & Morgan, G. J. (2007). Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood. https://doi.org/10.1182/blood-2007-02-075069

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.